MARIA PILAR FAYLONA: Open Payments
NPI 1770677676 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,189 in 62 payments from 16 companies in 2025. Trend: 2023 $1,366 · 2024 $1,227 · 2025 $1,189
Food & beverage: $1,189
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 11 | $274 |
| Bayer Healthcare Pharmaceuticals Inc. | 12 | $160 |
| Novo Nordisk Inc | 10 | $153 |
| Lilly USA, LLC | 5 | $112 |
| GlaxoSmithKline, LLC. | 5 | $106 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $74 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $69 |
| PFIZER INC. | 3 | $62 |
| SHIELD THERAPEUTICS INC | 2 | $40 |
| Kowa Pharmaceuticals America, Inc. | 1 | $24 |
Products named: Kerendia, FARXIGA, JARDIANCE, Ozempic, AIRSUPRA, SHINGRIX, MOUNJARO, XIFAXAN.
Industry payments across NV — which companies pay providers there.
